David Brous Net Worth

The estimated Net Worth of David B Jr Brous is at least $5.44 Million dollars as of 12 June 2023. Mr. Brous owns over 11,157 units of Henry Schein stock worth over $4,605,665 and over the last 3 years he sold HSIC stock worth over $835,213. In addition, he makes $0 as President and Strategic Business Units Group and Asia Pacific & Brazil Dental at Henry Schein.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Brous HSIC stock SEC Form 4 insiders trading

David has made over 1 trades of the Henry Schein stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 11,157 units of HSIC stock worth $835,213 on 12 June 2023.

The largest trade he's ever made was selling 11,157 units of Henry Schein stock on 12 June 2023 worth over $835,213. On average, David trades about 1,860 units every 0 days since 2022. As of 12 June 2023 he still owns at least 68,690 units of Henry Schein stock.

You can see the complete history of Mr. Brous stock trades at the bottom of the page.

David Brous biography

David Brous serves as President, Strategic Business Units Group and Asia Pacific & Brazil Dental of the Company. Mr. Brous joined us in 2002 and has held many positions within the organization, including leading and managing the Corporate Business Development Group and the International Healthcare Group (managing our International Animal Health business, International Medical business and Australia / New Zealand Dental business).

How old is David Brous?

David Brous is 51, he's been the President and Strategic Business Units Group and Asia Pacific & Brazil Dental of Henry Schein since 2019. There are 32 older and 1 younger executives at Henry Schein. The oldest executive at Henry Schein Inc. is Barry Alperin, 79, who is the Independent Director.

What's David Brous's mailing address?

David's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.

Insiders trading at Henry Schein

Over the last 22 years, insiders at Henry Schein have traded over $272,732,340 worth of Henry Schein stock and bought 23,637 units worth $1,414,559 . The most active insiders traders include Stanley M Bergman, Norman S Matthews, and Deborah Derby. On average, Henry Schein executives and independent directors trade stock every 21 days with the average trade being worth of $1,074,342. The most recent stock trade was executed by Lorelei Mc Glynn on 6 September 2024, trading 21,035 units of HSIC stock currently worth $1,457,726.

What does Henry Schein do?

henry schein, inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. the company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. a fortune 500® company and a member of the s&p 500® and nasdaq 100® indexes, henry schein employs more than 18,000 team schein members and serves more than one million customers. the company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. henry schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and henry schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. the company also offers its customers exclusive, innovative technology solutions, including practice

Complete history of Mr. Brous stock trades at Henry Schein

Henry Schein executives and stock owners

Henry Schein executives and other stock owners filed with the SEC include:

• Stanley Bergman,
  Chairman of the Board, Chief Executive Officer
• Stanley M. Bergman,
  Exec. Chairman & CEO
• Steven Paladino,
  Chief Financial Officer, Executive Vice President, Director
• Gerald Benjamin,
  Chief Administrative Officer, Executive Vice President, Director
• James Breslawski,
  President, Vice Chairman of the Board, Director
• Mark Mlotek,
  Chief Strategic Officer, Executive Vice President, Director
• James P. Breslawski,
  Exec. Vice Chairman & Pres
• Gerald A. Benjamin,
  Exec. VP, Chief Admin. Officer & Exec. Director
• Steven Paladino,
  Exec. VP, CFO & Exec. Director
• Mark E. Mlotek,
  Exec. VP, Chief Strategic Officer & Exec. Director
• Michael Racioppi,
  Senior Vice President, Chief Merchandising Officer
• Philip Laskawy,
  Lead Independent Director
• Barry Alperin,
  Independent Director
• Joseph Herring,
  Independent Director
• Kurt Kuehn,
  Independent Director
• Bradley Sheares,
  Independent Director
• Carol Raphael,
  Independent Director
• Anne Margulies,
  Independent Director
• Elizabeth Rekow,
  Independent Director
• Shira Goodman,
  Independent Director
• Paul Brons,
  Independent Director
• James Mullins,
  Senior Vice President of Global Services
• Rene Willi,
  President, Global Dental Surgical Group
• David Brous,
  President, Strategic Business Units Group and Asia Pacific & Brazil Dental
• Steven Kess,
  President of the Santa Fe Group
• Carolynne Borders,
  Vice President - Investor Relations
• Jonathan Koch,
  Senior Vice President and Chief Executive Officer, Global Dental Group and Interim Chief Executive Officer, Henry Schein One
• Michael Ettinger,
  Senior Vice President - Corporate and Legal Affairs, Chief of Staff, Secretary
• Lorelei McGlynn,
  Chief Human Resource Officer
• Walter Siegel,
  Senior Vice President, General Counsel
• Christopher Pendergast,
  Senior Vice President, Chief Technology Officer
• Brad Connett,
  President - Henry Schein's U.S. Medical Group
• Olga Timoshkina,
  VP of Corp. Fin., Chief Accounting Officer & Corp. Controller
• Michael Saul Ettinger,
  Exec. VP & COO
• Ronald N. South,
  Sr. VP & CFO
• John Lee,
  VP of Global Compensation & Benefits
• Walter Siegel,
  Chief Legal Officer
• Graham Stanley,
  VP of Investor Relations & Strategic Fin. Project Officer
• Christopher Pendergast,
  Sr. VP & CTO
• Ronald South,
  Chief Accounting Officer & VP of Corp. Fin.
• Paul Rose,
  SVP, Global Supply Chain
• David Mc Kinley,
  President, Medical Group
• Donald J Kabat,
  Director
• Karen Prange,
  EVP&CEO Gl.AH.Med.Den.Sur.Grp
• Lawrence S Bacow,
  Director
• Robert Minowitz,
  President, Int'l Dental Group
• E Dianne Rekow,
  Director
• Peter M. Mc Carthy,
  Pres., Global Animal Health
• Bridget A Ross,
  President, Global Medical Grp
• James A. Harding,
  Chief Technology Officer
• Mohamad Ali,
  
• Deborah Derby,
  
• Michael Zack,
  Senior Vice President
• Larry Gibson,
  Executive V.P. and CTO
• Irving Shafran,
  Director
• Margaret A Hamburg,
  Director
• Marvin Schein,
  
• Pamela Joseph,
  Director
• Stanley Komaroff,
  Senior Advisor
• Lonnie Shoff,
  Pres., Global Healthcare Spec.
• Norman S Matthews,
  Director
• Louis W Sullivan,
  Director
• Karyn Mashima,
  Director
• Leonard A David,
  Vice President
• Reed Vaughn Tuckson,
  
• Scott Philip Serota,
  
• Carole T Faig,
  
• Ronald N. South,
  SVP & Chief Financial Officer